STOCK TITAN

Exscientia Plc - EXAI STOCK NEWS

Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.

Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.

Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.

Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.

Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.

Rhea-AI Summary
EXAI: Exscientia plc (Nasdaq: EXAI) reported recent advancements in their pipeline, collaborations, and operations, along with financial results for Q3 2023. Key highlights include progress in their internal pipeline, new collaborations with Merck KGaA and Sanofi, and updates on their technology and precision medicine initiatives. Financially, revenue for Q3 2023 was $10.8 million, with R&D expenses at $39.8 million and G&A expenses at $13.6 million. Net operating cash outflows for the first nine months of 2023 were $145.1 million, with a cash balance of $447.8 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on November 9, 2023. The company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results. Investors can access the webcast on the company's website or join the conference call using the provided dial-in numbers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
conferences earnings
-
Rhea-AI Summary
Exscientia appoints Parker Moss as Executive Vice President, Corporate Development, to strengthen precision medicine and clinical innovation platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
none
Rhea-AI Summary
Exscientia announces preclinical data on LSD1 and MALT1 inhibitors at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences clinical trial AI
-
Rhea-AI Summary
Exscientia prioritizes highest value oncology targets, discontinues non-core programs. Partnered pipeline progresses with milestones achieved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
none
-
Rhea-AI Summary
Exscientia announces collaboration with Merck KGaA, with potential milestone payments of up to $674 million and royalties on product sales
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.47%
Tags
AI
Rhea-AI Summary
Exscientia plc to participate in investor conferences in September 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
none
-
Rhea-AI Summary
Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on August 10, 2023, before the open of U.S. markets. The company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. The webcast can be accessed on the company's website, and the conference call can be accessed by phone. A replay will be available on the website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences earnings
Rhea-AI Summary
Exscientia initiates EXCYTE-1, a multi-centre trial in ovarian cancer to investigate the relationship between ex vivo drug response and patient clinical response. The study aims to inform future studies in other solid tumors and is conducted in collaboration with the AGO Study Group. The company's precision medicine platform combines high-content imaging and deep learning image analysis to assess drug activity at a single cell level ex vivo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
none
Exscientia Plc

Nasdaq:EXAI

EXAI Rankings

EXAI Stock Data

633.18M
95.77M
25.9%
20.81%
2.15%
Biotechnology
Healthcare
Link
United Kingdom
Oxford